The B‐cell signatures were validated using CD20 IHC and dendritic signatures (DC‐7)‐signature using representative myeloid/macrophage IHC biomarkers (e.g., CD68 or CD163) in a second AITL cohort with HG‐U133plus2 GEP data (Figure 2H,I). The gene discussed is CD68; the disease is angioimmunoblastic T-cell lymphoma.